FDA goes on high alert as coro­n­avirus rais­es threat to drug man­u­fac­tur­ing and clin­i­cal tri­als grind to a halt

The FDA isn’t quite sure just what the coro­n­avirus out­break in Chi­na will mean for the US phar­ma in­dus­try, but it has the po­ten­tial to trig­ger a host of trou­ble­some is­sues around the sup­ply chain the coun­try is di­rect­ly plugged in­to.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER